Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04779320




Registration number
NCT04779320
Ethics application status
Date submitted
1/03/2021
Date registered
3/03/2021
Date last updated
12/04/2024

Titles & IDs
Public title
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Scientific title
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Secondary ID [1] 0 0
2020-004301-31
Secondary ID [2] 0 0
MLN0002-3025
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease (CD) 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vedolizumab IV

Experimental: Induction Period: 10 to 15 kg, Vedolizumab 150 mg - Vedolizumab 150 mg, intravenous (IV) infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of 10 to 15 kg will be included in this arm group.

Experimental: Induction Period: >15 to <30 kg, Vedolizumab 200 mg - Vedolizumab 200 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of \>15 to \<30 kg will be included in this arm group.

Experimental: Induction Period: =30 kg, Vedolizumab 300 mg - Vedolizumab 300 mg, IV infusion, at Day 1, Weeks 2 and 6 in Induction Period. Participants with CD having Baseline weight of =30 kg will be included in this arm group.

Experimental: Maintenance Period: 10 to 15 kg Vedolizumab 150 mg - Vedolizumab 150 mg, IV infusion, once every 8 weeks (Q8W) from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 150 mg.

Experimental: Maintenance Period: 10 to 15 kg Vedolizumab 100 mg - Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of 10 to 15 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.

Experimental: Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg - Vedolizumab 200 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 200 mg.

Experimental: Maintenance Period: >15 to <30 kg Vedolizumab 100 mg - Vedolizumab 100 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of \>15 to \<30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 100 mg.

Experimental: Maintenance Period: =30 kg, Vedolizumab 300 mg - Vedolizumab 300 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of =30 kg who achieved clinical response at Week 14 randomized to this high dose arm group will receive vedolizumab 300 mg.

Experimental: Maintenance Period: =30 kg: Vedolizumab 150 mg - Vedolizumab 150 mg, IV infusion, Q8W from Week 14 up to Week 46 in the Maintenance Period. Participants with Week 14 weight of =30 kg who achieved clinical response at Week 14 randomized to this low dose arm group will receive vedolizumab 150 mg.


Treatment: Drugs: Vedolizumab IV
Vedolizumab IV
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Clinical Remission at Week 54 Based on Pediatric Crohn's Disease Activity Index (PCDAI) Score =10
Timepoint [1] 0 0
Week 54
Primary outcome [2] 0 0
Percentage of Participants With Endoscopic Response at Week 54 Based on Simple Endoscopic Score for Crohn's Disease [SES-CD] Score
Timepoint [2] 0 0
Week 54
Secondary outcome [1] 0 0
Percentage of Participants with Clinical and Endoscopic Remission at Week 14 Based on Both PCDAI Score and SES-CD Score
Timepoint [1] 0 0
Week 14
Secondary outcome [2] 0 0
Percentage of Participants with Clinical and Endoscopic Remission at Week 54 Based on Both PCDAI Score and SES-CD Score
Timepoint [2] 0 0
Week 54
Secondary outcome [3] 0 0
Percentage of Participants with Sustained Clinical and Endoscopic Remission at Week 54
Timepoint [3] 0 0
Week 54
Secondary outcome [4] 0 0
Percentage of Participants with Corticosteroid-free Remission at Week 54 Based on PCDAI Score
Timepoint [4] 0 0
Week 54
Secondary outcome [5] 0 0
Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score
Timepoint [5] 0 0
Week 14
Secondary outcome [6] 0 0
Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score
Timepoint [6] 0 0
Week 54
Secondary outcome [7] 0 0
Percentage of Participants with Sustained Clinical Remission at Week 14 Based on PCDAI Score
Timepoint [7] 0 0
Week 14
Secondary outcome [8] 0 0
Percentage of Participants with Sustained Clinical Remission at Week 54 Based on PCDAI Score
Timepoint [8] 0 0
Week 54
Secondary outcome [9] 0 0
Serum Trough Concentrations of Vedolizumab Over Time
Timepoint [9] 0 0
Predose and postdose at multiple time points (up to 54 weeks)
Secondary outcome [10] 0 0
Percentage of Participants With Positive Antivedolizumab Antibodies
Timepoint [10] 0 0
Pre-dose (up to 54 weeks)
Secondary outcome [11] 0 0
Percentage of Participants With Positive Neutralizing Antivedolizumab Antibody Titers
Timepoint [11] 0 0
Pre-dose (up to 54 weeks)
Secondary outcome [12] 0 0
Sustained Clinical Response at Week 14 Based on PCDAI Score
Timepoint [12] 0 0
Week 14
Secondary outcome [13] 0 0
Sustained Clinical Response at Week 54 Based on PCDAI Score
Timepoint [13] 0 0
Week 54
Secondary outcome [14] 0 0
Percentage of Participants with Clinical Remission at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Timepoint [14] 0 0
Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Secondary outcome [15] 0 0
Percentage of Participants with Change in Baseline in Clinical Response at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Timepoint [15] 0 0
Baseline, weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54
Secondary outcome [16] 0 0
Percentage of Participants with at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AE of special interest (AESI)
Timepoint [16] 0 0
From first dose of study drug before each dose on dosing days through the Week 72
Secondary outcome [17] 0 0
Change from Baseline in Weight
Timepoint [17] 0 0
Baseline up to Week 54
Secondary outcome [18] 0 0
Change from Baseline in Linear Growth Z-score
Timepoint [18] 0 0
Baseline up to Week 54
Secondary outcome [19] 0 0
Change from Baseline in Tanner Stages at Week 54
Timepoint [19] 0 0
Week 54

Eligibility
Key inclusion criteria
Main

1. The participants has moderately to severely active CD, unresponsive or intolerant to their current standard of care (SOC).
2. The participants weigh =10 kg at the time of screening and enrollment into the study.
3. Participants with Crohn's disease (CD) diagnosed at least 1 month before screening. Participants with moderately to severely active CD defined by a Pediatric Crohn's Disease Activity Index (PCDAI) >30 and an simple endoscopic score for Crohn's Disease (SES-CD) >6 (or an SES-CD =4 if disease is confined to terminal ileum) at screening endoscopy.
4. Participants who have failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: corticosteroids, immunomodulators (eg, azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate [MTX]), and/or tumor necrosis factor (TNF)-a antagonist therapy (eg, infliximab, adalimumab). This includes participants who are dependent on corticosteroids or exclusive or partial enteral nutrition to control symptoms and who are experiencing worsening of disease in the moderate-to-severe range when attempting to wean off corticosteroids or discontinue exclusive enteral nutrition.
5. Participants with extensive colitis or pancolitis of >8 years' duration or left-sided colitis of >12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening.
6. Participants with vaccinations that are up-to-date based on the countrywide accepted schedule of childhood vaccines.

Main
Minimum age
2 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants who have received either (1) an investigational biologic (other than those listed in Exclusion Criterion #1) within 60 days or 5 half-lives before screening (whichever is longer); or (2) an approved biologic or biosimilar agent within 2 weeks before the first dose of study drug or at any time during the screening period.
2. Participants with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders including stroke, multiple sclerosis, brain tumor or neurodegenerative disease.
3. The participants had a clinically significant infection (eg, pneumonia, pyelonephritis, coronavirus disease 2019 [COVID-19]) within 30 days prior to first dose of study drug.
4. The participants has received any live vaccinations within 30 days prior to first dose.
5. Participants who currently require surgical intervention or are anticipated to require surgical intervention for CD during this study.
6. Participants who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, known fixed stenosis of the intestine, short bowel syndrome, or >3 small intestine resections.
7. Participants with a current diagnosis of indeterminate colitis.
8. Participants with clinical features suggesting monogenic very early-onset inflammatory bowel disease.
9. Active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of screening or during the screening Period that is positive, defined as:

* Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR
* A TB skin test reaction =5 mm.
10. Participants with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune participants(i.e., hepatitis B surface antigen [HBsAg]-negative and hepatitis B antibody-positive) may, however, be included.

Note: If a participant tests negative for HBsAg, but positive for HBcAb, the participant would be considered eligible if the absence of HBV DNA is confirmed by HBV DNA polymerase chain reaction reflex testing performed in the central laboratory.
11. Participants with chronic hepatitis C virus (HCV) (ie, positive HCV antibody [HCVAb] and HCV RNA).

Note: Participants who are HCVAb-positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 12 weeks before baseline]).
12. The participants has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation).
13. The participant has evidence of dysplasia or history of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
14. Participants with positive stool studies for ova and/or parasites or stool culture at screening visit.
15. Participants with positive Clostridioides difficile (C difficile) stool test at screening visit.

Other inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/11/2024
Actual
Sample size
Target
120
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Children's Hospital at Westmead - Westmead
Recruitment hospital [2] 0 0
Queensland Childrens Hospital - South Brisbane
Recruitment hospital [3] 0 0
Monash Health, Monash Medical Centre - Clayton
Recruitment hospital [4] 0 0
Royal Children's Hospital Melbourne - PIN - Parkville
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
Belgium
State/province [17] 0 0
Antwerpen
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussels
Country [19] 0 0
Belgium
State/province [19] 0 0
Vlaams Brabant
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Ontario
Country [23] 0 0
Canada
State/province [23] 0 0
Quebec
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Henan
Country [26] 0 0
China
State/province [26] 0 0
Shanghai
Country [27] 0 0
China
State/province [27] 0 0
Zhejiang
Country [28] 0 0
Croatia
State/province [28] 0 0
Grad Zagreb
Country [29] 0 0
Croatia
State/province [29] 0 0
Split
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha, Hlavni Mesto
Country [31] 0 0
Czechia
State/province [31] 0 0
Ostrava
Country [32] 0 0
Greece
State/province [32] 0 0
Attiki
Country [33] 0 0
Greece
State/province [33] 0 0
Athens
Country [34] 0 0
Greece
State/province [34] 0 0
Thessaloniki
Country [35] 0 0
Hungary
State/province [35] 0 0
Borsod-Abauj-Zemplen
Country [36] 0 0
Hungary
State/province [36] 0 0
Csongrad
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Israel
State/province [38] 0 0
HaMerkaz
Country [39] 0 0
Israel
State/province [39] 0 0
Yerushalayim
Country [40] 0 0
Israel
State/province [40] 0 0
Beer Sheba
Country [41] 0 0
Israel
State/province [41] 0 0
Haifa
Country [42] 0 0
Israel
State/province [42] 0 0
Jerusalem
Country [43] 0 0
Italy
State/province [43] 0 0
Campania
Country [44] 0 0
Italy
State/province [44] 0 0
Emilia-Romagna
Country [45] 0 0
Italy
State/province [45] 0 0
Lazio
Country [46] 0 0
Italy
State/province [46] 0 0
Lombardia
Country [47] 0 0
Italy
State/province [47] 0 0
Veneto
Country [48] 0 0
Japan
State/province [48] 0 0
Hukuoka
Country [49] 0 0
Japan
State/province [49] 0 0
Kumamoto
Country [50] 0 0
Japan
State/province [50] 0 0
Tokyo
Country [51] 0 0
Korea, Republic of
State/province [51] 0 0
Daegu Gwang'yeogsi
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Incheon Gwang'yeogsi
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Seongnam
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Seoul
Country [55] 0 0
Lithuania
State/province [55] 0 0
Kauno Apskritis
Country [56] 0 0
Lithuania
State/province [56] 0 0
Vilniaus Apskritis
Country [57] 0 0
Poland
State/province [57] 0 0
Dolnoslaskie
Country [58] 0 0
Poland
State/province [58] 0 0
Lodzkie
Country [59] 0 0
Poland
State/province [59] 0 0
Malopolskie
Country [60] 0 0
Poland
State/province [60] 0 0
Mazowieckie
Country [61] 0 0
Poland
State/province [61] 0 0
Podkarpackie
Country [62] 0 0
Poland
State/province [62] 0 0
Pomorskie
Country [63] 0 0
Poland
State/province [63] 0 0
Slaskie
Country [64] 0 0
Poland
State/province [64] 0 0
Zachodniopomorskie
Country [65] 0 0
Poland
State/province [65] 0 0
Lodz
Country [66] 0 0
Slovakia
State/province [66] 0 0
Banska Bystrica
Country [67] 0 0
Slovakia
State/province [67] 0 0
Bratislava
Country [68] 0 0
Spain
State/province [68] 0 0
Barcelona
Country [69] 0 0
Spain
State/province [69] 0 0
Valencia
Country [70] 0 0
Spain
State/province [70] 0 0
Madrid
Country [71] 0 0
Spain
State/province [71] 0 0
Malaga
Country [72] 0 0
Spain
State/province [72] 0 0
Sevilla
Country [73] 0 0
United Kingdom
State/province [73] 0 0
London, City Of
Country [74] 0 0
United Kingdom
State/province [74] 0 0
South Glamorgan
Country [75] 0 0
United Kingdom
State/province [75] 0 0
West Midlands
Country [76] 0 0
United Kingdom
State/province [76] 0 0
London
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab.

The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation.

Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.
Trial website
https://clinicaltrials.gov/study/NCT04779320
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Takeda Contact
Address 0 0
Country 0 0
Phone 0 0
+1-877-825-3327
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04779320